WHO WE ARE We are a cancer drug discovery company that is disrupting the traditional approach of treating cancers based upon their tissue of origin – a paradigm that fails most cancer patients. We have active programmes across a variety of cancer indications and disease biology fields, and we are seeking strategic alliances with pharma companies who wish to leverage our world-leading data and platforms. WHAT WE DO We apply the power of large-scale genomics and artificial intelligence to identify the genetic drivers of cancers and develop drugs to exploit their weaknesses. HOW WE DO IT We generate massive datasets using next generation tumour systems and advanced genomic technologies. Our AI-platform has been refined and validated over the past decade to prioritise key anti-cancer targets and to genetically identify those patient groups most likely to respond to treatments developed against those targets. Find our more about our science: https://mosaic-tx.com/our-science/